A patient sat down in an exam room and told her family nurse practitioner that she felt like a cheater.
She was forty-two. Two kids. She had lost forty-eight pounds. Her A1c — the three-month measure of blood sugar — had moved from the diabetic range into the normal range for the first time in a decade. Her blood pressure was normal. Her sleep was better. She was sleeping a full eight hours for the first time since her second pregnancy. By every clinical measure that matters, she was doing better than she had done in her entire adult life.
She felt like a cheater. Because the difference was a weekly injection of a drug called semaglutide.
I want to talk about that feeling. I want to talk about how the GLP-1 class of medications actually works, what they do well, what they cannot do, and — because Rock The New Food Pyramid is a platform built around marketing transparency as much as nutrition science — what the food industry is doing in response. I am going to land somewhere that may not satisfy everyone. That is the honest version of this conversation.
What GLP-1 drugs actually do
Glucagon-like peptide-1 — GLP-1 — is a hormone your body produces naturally, in your gut, after you eat. It does several things. It signals your pancreas to release insulin. It slows the rate at which your stomach empties. And, through pathways in the hypothalamus, it tells your brain that you are full (Drucker, 2018).
GLP-1 receptor agonist drugs — Ozempic, Wegovy, Mounjaro, and the newer entrants — are synthetic mimics of that hormone, modified so that they last days instead of minutes in the bloodstream. Semaglutide, the active ingredient in Ozempic and Wegovy, was originally developed for type 2 diabetes; the weight-loss effects were noted in clinical trials and led to the separate approval of Wegovy for chronic weight management in 2021 (U.S. Food and Drug Administration, 2021). Tirzepatide, the active ingredient in Mounjaro, works on both the GLP-1 and GIP receptors and has shown larger weight-loss effects in trials (Jastreboff et al., 2022).
The mechanism, in plain English: the drug makes you feel full sooner, stay full longer, and reduces what the literature calls "food noise" — the persistent intrusive thinking about food that many people with obesity report and that, increasingly, the clinical community recognizes as a real and disabling phenomenon.
The trial data is striking. In the STEP 1 trial (Wilding et al., 2021), participants on semaglutide lost an average of nearly 15% of their body weight over 68 weeks, compared with about 2.4% on placebo. In SURMOUNT-1 (Jastreboff et al., 2022), tirzepatide produced an average of 20.9% weight loss at the highest dose. For context, the bariatric surgery literature historically reports 25 to 30% sustained weight loss. We are now in the same conversation as surgery, with a weekly injection.
These are not modest numbers. The drugs work.
What they do not do
They do not change the food environment that produced the obesity epidemic.
They do not address the fact that, in 2024, ultra-processed foods accounted for over half of the calories consumed in the average American adult diet (Juul et al., 2022). They do not address the fact that the food supply has been engineered, over the past forty years, to deliver maximum craving with minimum satiety — the bliss point problem (Moss, 2013) — which is, mechanistically, the inverse of what GLP-1 drugs do.
They do not change the fact that a child today is being raised inside the food environment that adults are now using prescription medication to escape.
This is the part of the conversation that does not fit into a thirty-second drug commercial. The drugs are not a band-aid in the dismissive sense. They are real medicine that produces real outcomes. They are also a bypass around a structural problem that the existence of a successful pharmaceutical intervention may, perversely, make the food industry less motivated to solve.
I want to be careful here, because there is a flavor of this argument that becomes, at the extreme, blame the patient for taking the drug. That is not the argument. The patient on the drug is doing what real medicine is for: addressing real disease with the tools that work. The argument is about what the existence of the drug means for the next generation's food environment.
What the food industry is doing in response
This is the part of the conversation I am uniquely positioned to weigh in on, and I want to be specific.
The packaged-food industry is, as I write this, retooling for the GLP-1 consumer. Nestlé announced a line of "GLP-1 companion" foods — Vital Pursuit — in mid-2024 (Nestlé S.A., 2024). Other major packaged-food companies have made public statements in the same period about reformulating portion sizes, adjusting product lines, and developing "smaller, more nutrient-dense" products aimed at consumers eating less because of GLP-1 medication. Business press coverage of this retooling has been extensive.
The marketing language is interesting. "Companion." "Compatible." "Optimized for the new way you eat." This is the same machinery that built the low-fat aisle in the 1990s and the gluten-free aisle in the 2010s, now retooled for a pharmaceutical-modified eating pattern. None of it, you will note, addresses the question of whether the ultra-processed product itself is the problem.
You will see the GLP-1 companion category appear on grocery shelves over the next twelve to twenty-four months. Most of it will be ultra-processed (NOVA 4) by the underlying classification, regardless of the front-of-package marketing. The barcode scanner in Rock The New Food Pyramid will tell you that. The marketing will work hard to obscure it.
If a member of your family is on a GLP-1, the case for using a NOVA-aware tool to choose food is, if anything, stronger, not weaker. Reduced appetite means every bite matters more. The protein, the fiber, the nutrient density of those reduced-volume meals is what determines whether weight loss is followed by metabolic health or by sarcopenia (muscle loss) and nutritional deficiency. Clinicians prescribing these drugs are increasingly emphasizing that point in patient-counseling guidance.
The "cheater" feeling
Back to the patient in the exam room.
The feeling she described — I feel like a cheater — is not an accident of personal psychology. It is the cumulative residue of forty years of cultural messaging that frames obesity as a moral failing of willpower, and weight loss as a moral achievement of discipline. If you internalize that framing, then a drug that makes weight loss easier becomes, by the math of that framing, a moral shortcut.
The framing is wrong. It has been wrong, as a matter of evidence, for at least two decades. The metabolic, endocrine, and neuroendocrine literature on obesity treats it as a chronic disease of multiple physiological systems, not a character defect (American Medical Association, 2013; Sharma & Padwal, 2010). The willpower framing persists because it is useful — useful to industries that profit from food sales and from diet products alike — not because it is accurate.
The patient is not a cheater. She has a chronic disease and she is being treated for it. The treatment works. Her family is going to have her for more years than they would have. That is the end of the analysis. The shame attached to the medication is, in its entirety, the residue of the cultural framing the food industry helped build.
Where I land
I will be honest with you. My co-host Imani Bell and I do not entirely agree on this one. She is, by clinical instinct, optimistic about what these drugs do in the exam room. She has watched the cheater-feeling patient walk in lighter than she has been in fifteen years. She has watched the lab values turn around. She is enthusiastic about the right patients getting the right medication, and impatient with the cultural shame that complicates it.
I sit slightly to one side of that. I see the patient. I see the outcome. I also see the boardroom. I see the food industry preparing to make money off the new eating pattern just as efficiently as it made money off the old one, and I worry — explicitly — that the existence of a successful pharmaceutical intervention reduces the pressure to fix the food environment that produced the disease in the first place.
We are both right. That is not a writerly hedge. It is the actual shape of the issue.
For the family using Rock The New Food Pyramid: if you are on a GLP-1, use the platform. Use it harder than you would have before. Reduced appetite is real, and every meal needs to do more work. If you are not on a GLP-1, the platform was built for you too, and the case for nutrient-dense, minimally processed food is what it has always been.
For the patient in Imani's exam room: you are not a cheater. You are someone with a disease, being treated. Your A1c is fifteen years better. Your kids get you for longer. The drug company is going to make money. The food industry is going to retool. The cultural shame is going to fade.
You are doing fine.
---
A note on medical content
This article is editorial and educational. It is not medical advice. GLP-1 receptor agonist medications — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are prescription drugs, and the decision to start, continue, or stop them belongs between you and a qualified healthcare provider. The author of this article is Dr. Suzanne R. Brock, who holds a doctoral degree in marketing, not in medicine. Rock The New Food Pyramid is a nutrition-education platform; nothing here should be interpreted as a clinical recommendation for any individual.
---
References
American Medical Association. (2013). Recognition of obesity as a disease (Resolution 420, A-13). American Medical Association House of Delegates.
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Juul, F., Parekh, N., Martinez-Steele, E., Monteiro, C. A., & Chang, V. W. (2022). Ultra-processed food consumption among US adults from 2001 to 2018. American Journal of Clinical Nutrition, 115(1), 211–221. https://doi.org/10.1093/ajcn/nqab305
Moss, M. (2013). Salt sugar fat: How the food giants hooked us. Random House.
Nestlé S.A. (2024). Nestlé launches Vital Pursuit, a new line of foods to support people on GLP-1 weight loss medications [Press release]. Nestlé.
Sharma, A. M., & Padwal, R. (2010). Obesity is a sign — over-eating is a symptom: An aetiological framework for the assessment and management of obesity. Obesity Reviews, 11(5), 362–370. https://doi.org/10.1111/j.1467-789X.2009.00689.x
U.S. Food and Drug Administration. (2021). FDA approves new drug treatment for chronic weight management, first since 2014 [Press release]. U.S. Food and Drug Administration.
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183